Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer

Study ID
NCT02355119

Study type
Interventional

Study phase
Phase 3

Study status
Unknown status

Trial Acronym

GIP-2

Trial Summary

Patients with resected pancreatic cancer who fulfill the selection criteria will be randomized to receive one of the two treatment arms for a period of 6 months: Gemcitabine, the standard arm, or FOLFOXIRI (the combination of 5-Fluorouracil/Folinic Acid, Oxaliplatin and Irinotecan), the experimental arm. A total of 310 patients will be enrolled in about 50 Italian centers.

More informations

Trial Starting Date

Jan 31,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age 75 Years

Enrollement Limit

310